myTomorrows Expands AI Capabilities to Support Clinical Trial Sites, Streamline Trial Recruitment and Strengthen Site Workflows

The new site solution enables centralized referral management, real-time trial updates and enhanced physician communication to improve patient retention for clinical research teams worldwide

AMSTERDAM, Sept. 18, 2025 /PRNewswire/ -- myTomorrows, a global health technology company connecting patients with all possible pre-approval treatments, today announced a new solution to support trial site clinical research teams through its AI-powered platform. The referral management tool works critically alongside myTomorrows' in-house Patient Navigation service and is designed to address persistent barriers in trial awareness, patient recruitment and retention. It enables research teams to share and update custom trial information in real time, unify fragmented referral processes, and accelerate pre-screening, all within the secure and compliant myTomorrows platform.

Clinical trial recruitment remains a major challenge: phase III trials average 13–18 months, with 37% of sites under-enrolling and one-third enrolling none. 72% of physicians cite search and pre-screening as too time-consuming, while fragmented referral workflows create heavy burdens on sites. Public trial registries (e.g. Clinical Trials, ISRCTN, CTIS) often contain outdated information leading to unsuitable referrals. Meanwhile, referrals flow in from various sources: networks, advocacy groups, messaging apps, even emails, creating challenges for investigators, disjointed workflows, and high screen failure rates. Compounded by incomplete or inaccurate pre-screening, site resources are wasted, patients become frustrated, and inefficiencies are reinforced.

To meet these challenges, myTomorrows has expanded its proprietary AI trial matching platform to further support the needs of sites, providing a new single interface that unifies internal and external referrals, enables real-time trial updates, and offers secure reporting and communication. As a standalone site solution, it also streamlines workflows to seamlessly refer pre-screened patients, improving match accuracy, and strengthening overall recruitment efficiency.

The solution broadens trial visibility and offers an opportunity for sites to expand their referral networks. Whereas traditional registries provide only static information, myTomorrows empowers sites to actively add and adjust trial details on the platform. This delivers physicians real-time updates and referral requirements, helping sites communicate recruitment needs with greater clarity and impact. It can include updates such as cohort statuses, language and country of origin requirements or required documentation, all of which enables more targeted and relevant referrals, and offers an opportunity to better analyze unlisted referrals.

It also facilitates streamlined communication and collaboration with physicians, enhancing referral quality and responsiveness through direct messaging. Workflows support referring physicians to efficiently pre-screen their patients within the platform using AI and confidently make relevant referrals to actively recruiting sites.

myTomorrows is the most accurate LLM-enabled platform for pre-screening and trial matching, uniting searches for pre-approval treatments into a single, stakeholder-driven tool that addresses unmet medical needs globally. This solution builds on global momentum, with the ASCO Clinical Cancer Informatics review underscoring that criterion-level matching, explainability, and hybrid logic are key to getting LLM-driven trial matching right, capabilities that are already embedded in the myTomorrows setup. The platform, fueled by AI, delivers 98% eligibility accuracy and up to 90% of time saved on evaluating eligibility criterion against provided patient data, such as previous treatments, histology and biomarkers. Crucially, API integration options with EHRs and CTMSs enable sites and sponsors to run large-scale automated screening at speeds moving beyond manual or traditional questionnaires and towards bulk assessments. Built with security and privacy by design, the system meets GDPR, HIPAA, ISO 27001 and SOC 2 standards.

"At myTomorrows, we strive to continuously adapt our AI technology to the diverse needs of the pre-approval ecosystem," said Marshall Van Beurden, CTO of myTomorrows. "As AI models continue to develop new functionalities, myTomorrows too will innovate. We intentionally developed our platform with a flexible AI tech stack, designed to evolve alongside advancements in capabilities. This flexibility allows models to be optimized and swapped as the technology progresses, ensuring clinical research teams have the most effective compliant tools available."

Early adopters report increased acceptance rates, measurable improvements in enrollment and a substantial reduction in recruitment cycle times, demonstrating the platform's ability to enhance site productivity while delivering a better patient experience.

Alongside its platform, myTomorrows' dedicated team of medical community managers have to date onboarded more than 320 trial sites and built a supportive network for over 2,600 physicians worldwide. To complement, the multilingual Patient Navigator team have helped over 16,200 patients and families, providing them with one-on-one support across global time zones. This level of high-touch engagement has proven to reduce recruitment drop-offs and strengthen participant retention.

"myTomorrows is on a mission to break down barriers that hinder equitable patient access. A cornerstone of that effort is removing the friction that slows recruitment and limits trial participation," said Michel van Harten, MD, CEO of myTomorrows. "By combining precision AI with human expertise, sites can recruit more efficiently, physicians can access up-to-date trial information, and patients can stay engaged and informed throughout their journey. This is a critical step toward building clinical trial workflows that can scale globally."

For more information on how myTomorrows can transform site referral management, click here.

About myTomorrows

myTomorrows is a global healthtech company dedicated to breaking down barriers for patients seeking treatment options. The company has built a proprietary technology that conducts a comprehensive and accurate search of clinical trials, and, where appropriate, Expanded Access Programs, from global public registries. This functionality efficiently connects patients, physicians, trial sites, and BioPharma to simplify and accelerate access to drugs in development. Headquartered in Amsterdam with an office in New York City, myTomorrows has helped more than 16,200 patients and 2,600 physicians across 320+ sites in over 133 countries.

mytomorrows.com

myTomorrows Media Contact:

Kate Schoenstadt
Headline Media
[email protected]
+972 54 777 6684

SOURCE myTomorrows